

AD_____

Award Number: DAMD17-98-1-8284

TITLE: Designer T Cells for Breast Cancer Therapy: Phase I
Studies

PRINCIPAL INVESTIGATOR: Richard P. Junghans, M.D., Ph.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215

REPORT DATE: July 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Final (1 Jul 98 - 30 Jun 02)	
4. TITLE AND SUBTITLE Designer T Cells for Breast Cancer Therapy: Phase I Studies			5. FUNDING NUMBERS DAMD17-98-1-8284	
6. AUTHOR(S) Richard P. Junghans, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Beth Israel Deaconess Medical Center Boston, Massachusetts 02215 E-Mail: junghans@hms.harvard.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
20030103 005				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) In the present report we describe studies using chimeric immune receptors consisting of an antibody fragment against the CEA tumor antigen joined to signaling portions of the T cell receptor(IgTCR). The antibody fragment confers CEA specificity to the receptor, while the signaling domains transmit T cell activation signals. These receptors allow the T cells (designer T cells) to bypass immune tolerance to CEA and to activate effector functions in a tumor specific manner. We have partially completed a phase I study using IgTCR-modified designer T cells. These studies demonstrate the specific signaling molecules activate specific T cell effector functions in a tumor specific manner. The study will be completed on a continuing no-cost extension with the funds allocated.				
14. SUBJECT TERMS breast cancer, chimeric immune receptors, CEA tumor antigen, T cells			15. NUMBER OF PAGES 10	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	8
References.....	9
Appendices.....	10

4. INTRODUCTION

Carcinoembryonic antigen (CEA) is a tumor-associated antigen which is expressed on ≈ 30 -60% of metastatic breast tumors. The purpose of this research is to develop a new type of cancer therapy using autologous T cells modified with a chimeric immunoglobulin T cell receptor (IgTCR) directed against CEA + tumors. The specific objectives are to:

1. Complete setup for therapy.
2. Apply IgTCR-modified cells in a phase I clinical study in patients with metastatic CEA + breast tumors

In addition, to the above we have also carried out basic research efforts to create second-generation reagents that will enhance the therapy for future phase II/III studies.

5. BODY

The following activities were undertaken under the current year no-cost extension to the above referenced grant. It is noted that only two years of funding were provided by the DOD, whereas the task list was stated for the entire 4 year requested funding period. Accordingly, certain of the tasks were abandoned due to lack of funding, as indicated below.

I. Lab and clinical set up for therapy.

This was previously reported as completed.

However, we were previously mandated to redo this step by our local institution (not by the FDA), with a patient-dedicated facility. This was previously in a shared-use facility according that was acceptable under FDA specifications. We hired new staff during the past year and did retraining to re-establish this facility. Although we passed an outside inspector's certification, the institution still would not allow use of this facility. Hence, we have transferred production to the Cell Manipulation Core of the Dana Farber/Harvard Cancer Center. We are now in final stages of certification there.

II. Phase I clinical trial

This trial was partially completed but interrupted due to reasons mentioned in the prior report. In the past year, we have responded to requests for redesign of the Cell Transduction Facility (CTF) for patient sample preparation. We have also established a DSMB to conduct patient monitoring on this gene therapy study. With various other administrative responses and design changes (only very modest changes to the treatment protocol), we expect to be ready to resume the study in 9/2002 and should complete the trial within the coming year. There remain 5 patients to treat on the phase I study.

All patient care funds have been preserved, and will be applied to complete the phase I tests.

III. Phase II study

Funding was not provided to support this study. This task is abandoned.

IV. Phase II study +IL2

Funding was not provided to support this study. This task is abandoned.

V. Laboratory studies for therapy improvement.

A. Prepare improved VPCs.

Completed in prior report.

B. Prepare improved helper cell lines.

Funding was not provided to support this effort. This task is abandoned.

C. Prepare CEA-IgG chimeric protein.

This product was completed in this recent year. Protein has been expressed. Biologic tests are to follow.

6. KEY RESEARCH ACCOMPLISHMENTS

- Technology transfer for cell production to Cell Manipulation Core
- New staff hiring and training.
- Protocol and consent modifications.
- Patient Treatment objectives deferred. To be accomplished with remaining funds.
- Preparation of CEA-IgG construct.

7. REPORTABLE OUTCOMES

- Publications:

Ma QZ, Gonzalo-Danganzo R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In Harrison P (ed) Cancer Chemotherapy & Biological Response Modifiers – Annual 20 Oxford: Elsevier Science. 2001:319-345.

8. CONCLUSIONS

The key clinical efforts of this study are deferred and will be completed in the coming year with conserved Department of Defense funds under this no-cost extension.

Note:

Extension not yet approved due to human use problems.

9. REFERENCES

None.

10. APPENDICES

A. Manuscripts

Ma QZ, Gonzalo-Danganzo R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In Harrison P (ed) Cancer Chemotherapy & Biological Response Modifiers – Annual 20 Oxford: Elsevier Science. 2001:319-345.

Note:

Copy of manuscript not attached.